Progress towards a consensus on biomarkers for Alzheimer's disease: A review of peripheral analytes

Biomarkers in Medicine

Volumn 7, Issue 4, 2013, Pages 641-662

  Rembach, Alan ^a   Ryan, Tim M ^a   Roberts, Blaine R ^a   Doecke, James D ^b   Wilson, William J ^b   Watt, Andrew D ^a   Barnham, Kevin J ^a   Masters, Colin L ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b CSIRO   (Australia)

Author keywords

Alzheimer's disease; amyloid ; biomarkers; CSF; diagnosis; peripheral biomarkers; plasma; proteomics; serum; standardization

Indexed keywords

ALPHA 1 ANTITRYPSIN; ALPHA 2 MACROGLOBULIN; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; APOLIPOPROTEIN E; BIOLOGICAL MARKER; CHOLESTEROL; CLUSTERIN; COMPLEMENT FACTOR H; COPPER; CYTOKINE; DESMOSTEROL; ETHANOLAMINE; HAPTOGLOBIN; IRON; ISOPROSTANE DERIVATIVE; LYSOPHOSPHATIDYLCHOLINE; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MICRORNA; PANCREAS POLYPEPTIDE; PHYTOSPHINGOSINE; PRASTERONE; RNA; SOMATOMEDIN BINDING PROTEIN 2; SPHINGANINE; TAU PROTEIN; VASCULAR CELL ADHESION MOLECULE 1; ZINC;

ALZHEIMER DISEASE; CEREBROSPINAL FLUID ANALYSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; DISEASE SEVERITY; EARLY DIAGNOSIS; EXOSOME; GENE EXPRESSION; HUMAN; INFLAMMATION; LIPID RAFT; MILD COGNITIVE IMPAIRMENT; NONHUMAN; OXIDATIVE STRESS; PATHOPHYSIOLOGY; POSITRON EMISSION TOMOGRAPHY; PROGNOSIS; PROTEIN BLOOD LEVEL; PROTEIN MICROARRAY; PROTEOMICS; REVIEW; SENSITIVITY AND SPECIFICITY; TWO DIMENSIONAL GEL ELECTROPHORESIS;

ALZHEIMER DISEASE; ANIMALS; BIOLOGICAL MARKERS; CONSENSUS; HUMANS; PROTEOMICS; TRANSCRIPTOME;

EID: 84881298420     PISSN: 17520363     EISSN: 17520371     Source Type: Journal    
DOI: 10.2217/bmm.13.59     Document Type: Review

References (253)

1. Barnes DE, Yaffe K. The projected effect of risk factor reduction on Alzheimer's disease prevalence. Lancet Neurol. 10(9), 819-828 (2011
2. Alzheimer's Association. 2012 Alzheimer's disease facts and figures. Alzheimers Dement. 8(2), 131-168 (2012
3. Dubois B, Feldman HH, Jacova C et al. Research criteria for the diagnosis of Alzheimer's disease: Revising the NINCDS-ADRDA criteria. Lancet Neurol. 6(8), 734-746 (2007
4. Haass C, Selkoe DJ. Soluble protein oligomers in neurodegeneration: Lessons from the Alzheimer's amyloid beta-peptide. Nat. Rev. Mol. Cell Biol. 8(2), 101-112 (2007
5. Dinamarca MC, Rios JA, Inestrosa NC. Postsynaptic receptors for amyloid-beta oligomers as mediators of neuronal damage in Alzheimer's disease. Front. Physiol. 3, 464 (2012
6. Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework. Clin. Pharmacol. Ther. 69(3), 89-95 (2001
7. Klunk WE. Biological markers of Alzheimer's disease. Neurobiol. Aging 19(2), 145-147 (1998
8. Humpel C. Identifying and validating biomarkers for Alzheimer's disease. Trends Biotechnol. 29(1), 26-32 (2011
9. Blennow K, Hampel H, Weiner M, Zetterberg H. Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat. Rev. Neurol. 6(3), 131-144 (2010
10. Marksteiner J, Hinterhuber H, Humpel C. Cerebrospinal fluid biomarkers for diagnosis of Alzheimer's disease: Beta-Amyloid(1-42), tau, phospho-Tau-181 and total protein. Drugs Today 43(6), 423-431 (2007
11. Peskind ER, Riekse R, Quinn JF et al. Safety and acceptability of the research lumbar puncture. Alzheimer Dis. Assoc. Disord. 19(4), 220-225 (2005
12. Thambisetty M, Lovestone S. Blood-based biomarkers of Alzheimer's disease: Challenging but feasible. Biomarkers Med. 4(1), 65-79 (2010
13. Jelic V, Hagman G, Yamamoto NG et al. Abnormal platelet amyloid-beta protein precursor (AbetaPP) metabolism in Alzheimer's disease: Identification and characterization of a new AbetaPP isoform as potential biomarker. J. Alzheimers Dis. 35(2), 285-295 (2013
14. Casoli T, Balietti M, Giorgetti B, Solazzi M, Scarpino O, Fattoretti P. Platelets in Alzheimer's disease-Associated cellular senescence and inflammation. Curr. Pharm. Des. 19(9), 1727-1738 (2013
15. Catricala S, Torti M, Ricevuti G. Alzheimer disease and platelets: How's that relevant. Immun. Ageing 9(1), 20 (2012
16. Hye A, Lynham S, Thambisetty M et al. Proteome-based plasma biomarkers for Alzheimer's disease. Brain 129(11), 3042-3050 (2006
17. Tammen H, Schulte I, Hess R et al. Peptidomic analysis of human blood specimens: Comparison between plasma specimens and serum by differential peptide display. Proteomics 5(13), 3414-3422 (2005
18. Patel S, Shah RJ, Coleman P, Sabbagh M. Potential peripheral biomarkers for the diagnosis of Alzheimer's disease. Int. J. Alzheimers Dis. 2011, 572495 (2011
19. Zipser BD, Johanson CE, Gonzalez L et al. Microvascular injury and blood-brain barrier leakage in Alzheimer's disease. Neurobiol. Aging 28(7), 977-986 (2007
20. Hye A, Lynham S, Thambisetty M et al. Proteome-based plasma biomarkers for Alzheimer's disease. Brain 129(Pt 11), 3042-3050 (2006
21. Aluise CD, Sowell RA, Butterfield DA. Peptides and proteins in plasma and cerebrospinal fluid as biomarkers for the prediction, diagnosis, and monitoring of therapeutic efficacy of Alzheimer's disease. Biochim. Biophys. Acta 1782(10), 549-558 (2008
22. Millioni R, Tolin S, Puricelli L et al. High abundance proteins depletion vs low abundance proteins enrichment: Comparison of methods to reduce the plasma proteome complexity. PLoS ONE 6(5), e19603 (2011
23. Liumbruno G, D'Alessandro A, Grazzini G, Zolla L. Blood-related proteomics. J. Proteomics 73(3), 483-507 (2010
24. Rogers JT, Bush AI, Cho HH et al. Iron and the translation of the amyloid precursor protein (APP) and ferritin mRNAs: Riboregulation against neural oxidative damage in Alzheimer's disease. Biochem. Soc. Trans. 36(Pt 6), 1282-1287 (2008
25. Masters CL, Cappai R, Barnham KJ, Villemagne VL. Molecular mechanisms for Alzheimer's disease: Implications for neuroimaging and therapeutics. J. Neurochem. 97(6), 1700-1725 (2006
26. Tanzi RE, Bertram L. Twenty years of the Alzheimer's disease amyloid hypothesis: A genetic perspective. Cell 120(4), 545-555 (2005
27. Selkoe DJ. Alzheimer's disease: A central role for amyloid. J. Neuropathol. Exp. Neurol. 53(5), 438-447 (1994
28. Chen M, Inestrosa NC, Ross GS, Fernandez HL. Platelets are the primary source of amyloid beta-peptide in human blood. Biochem. Biophys. Res. Commun. 213(1), 96-103 (1995
29. Haass C, Schlossmacher MG, Hung AY et al. Amyloid beta-peptide is produced by cultured cells during normal metabolism. Nature 359(6393), 322-325 (1992
30. Mehta PD, Pirttila T, Patrick BA, Barshatzky M, Mehta SP. Amyloid beta protein 1-40 and 1-42 levels in matched cerebrospinal fluid and plasma from patients with Alzheimer disease. Neurosci. Lett. 304(1-2), 102-106 (2001
31. Ghersi-Egea JF, Gorevic PD, Ghiso J, Frangione B, Patlak CS, Fenstermacher JD. Fate of cerebrospinal fluid-borne amyloid beta-peptide: Rapid clearance into blood and appreciable accumulation by cerebral arteries. J. Neurochem. 67(2), 880-883 (1996
32. Shibata M, Yamada S, Kumar SR et al. Clearance of Alzheimer's amyloid-ss(1-40) peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier. J. Clin. Invest. 106(12), 1489-1499 (2000
33. Mayeux R, Honig LS, Tang MX et al Plasma A[beta]40 and A[beta]42 and Alzheimer's disease: Relation to age, mortality, and risk. Neurology 61(9), 1185-1190 (2003
34. Giedraitis V, Sundelof J, Irizarry MC et al. The normal equilibrium between CSF and plasma amyloid beta levels is disrupted in Alzheimer's disease. Neurosci. Lett. 427(3), 127-131 (2007
35. Fagan AM, Mintun MA, Shah AR et al. Cerebrospinal fluid tau and ptau(181) increase with cortical amyloid deposition in cognitively normal individuals: Implications for future clinical trials of Alzheimer's disease. EMBO Mol. Med. 1(8-9), 371-380 (2009
36. Wilson MR, Yerbury JJ, Poon S. Potential roles of abundant extracellular chaperones in the control of amyloid formation and toxicity. Mol. Biosyst. 4(1), 42-52 (2008
37. Song F, Poljak A, Valenzuela M, Mayeux R, Smythe GA, Sachdev PS. Meta-Analysis of plasma amyloid-beta levels in Alzheimer's disease. J. Alzheimers Dis. 26(2), 365-375 (2011
38. Fukumoto H, Tennis M, Locascio JJ, Hyman BT, Growdon JH, Irizarry MC. Age but not diagnosis is the main predictor of plasma amyloid beta-protein levels. Arch. Neurol. 60(7), 958-964 (2003
39. Kosaka T, Imagawa M, Seki K et al. The beta APP717 Alzheimer mutation increases the percentage of plasma amyloid-beta protein ending at A beta42(43). Neurology 48(3), 741-745 (1997
40. Scheuner D, Eckman C, Jensen M et al. Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease. Nat. Med. 2(8), 864-870 (1996
41. Sobow T, Flirski M, Kloszewska I, Liberski PP. Plasma levels of alpha beta peptides are altered in amnestic mild cognitive impairment but not in sporadic Alzheimer's disease. Acta Neurobiol. Exp. (Wars.) 65(2), 117-124 (2005
42. Tamaoka A, Fukushima T, Sawamura N et al. Amyloid beta protein in plasma from patients with sporadic Alzheimer's disease. J. Neurol. Sci. 141(1-2), 65-68 (1996
43. Vanderstichele H, Van Kerschaver E, Hesse C et al. Standardization of measurement of beta-Amyloid(1-42) in cerebrospinal fluid and plasma. Amyloid 7(4), 245-258 (2000
44. Ertekin-Taner N, Younkin LH, Yager DM et al. Plasma amyloid beta protein is elevated in late-onset Alzheimer disease families. Neurology 70(8), 596-606 (2008
45. Cosentino SA, Stern Y, Sokolov E et al. Plasma ss-Amyloid and cognitive decline. Arch. Neurol. 67(12), 1485-1490 (2010
46. Sundelof J, Giedraitis V, Irizarry MC et al. Plasma beta amyloid and the risk of Alzheimer disease and dementia in elderly men: A prospective, population-based cohort study. Arch. Neurol. 65(2), 256-263 (2008
47. van Oijen M, Hofman A, Soares HD, Koudstaal PJ, Breteler MM. Plasma Abeta(1-40) and Abeta(1-42) and the risk of dementia: A prospective case-cohort study. Lancet Neurol. 5(8), 655-660 (2006
48. Laske C, Sopova K, Gkotsis C et al. Amyloid-βpeptides in plasma and cognitive decline after 1 year follow-up in Alzheimer's disease patients. J. Alzheimers Dis. 21(4), 1263-1269 (2010
49. Mayeux R, Tang MX, Jacobs DM et al. Plasma amyloid beta-peptide 1-42 and incipient Alzheimer's disease. Ann. Neurol. 46(3), 412-416 (1999
50. Schupf N, Tang MX, Fukuyama H et al. Peripheral Abeta subspecies as risk biomarkers of Alzheimer's disease. Proc. Natl Acad. Sci. USA 105(37), 14052-14057 (2008
51. Lewczuk P, Kornhuber J, Vanmechelen E et al. Amyloid beta peptides in plasma in early diagnosis of Alzheimer's disease: A multicenter study with multiplexing. Exp. Neurol. 223(2), 366-370 (2010
52. Pesaresi M, Lovati C, Bertora P et al. Plasma levels of beta-Amyloid (1-42) in Alzheimer's disease and mild cognitive impairment. Neurobiol. Aging 27(6), 904-905 (2006
53. Schupf N, Zigman WB, Tang MX et al. Change in plasma Ass peptides and onset of dementia in adults with Down syndrome. Neurology 75(18), 1639-1644 (2010
54. Seppala TT, Herukka SK, Hanninen T et al. Plasma Abeta42 and Abeta40 as markers of cognitive change in follow-up: A prospective, longitudinal, population-based cohort study. J. Neurol. Neurosurg. Psychiatry 81(10), 1123-1127 (2010
55. Lui JK, Laws SM, Li QX et al. Plasma amyloid-beta as a biomarker in Alzheimer's disease: The AIBL study of aging. J. Alzheimers Dis. 20(4), 1233-1242 (2010
56. Blennow K, De Meyer G, Hansson O et al. Evolution of Abeta42 and Abeta40 levels and Abeta42/Abeta40 ratio in plasma during progression of Alzheimer's disease: A multicenter assessment. J. Nutr. Health Aging 13(3), 205-208 (2009
57. Graff-Radford NR, Crook JE, Lucas J et al. Association of low plasma Abeta42/Abeta40 ratios with increased imminent risk for mild cognitive impairment and Alzheimer disease. Arch. Neurol. 64(3), 354-362 (2007
58. Lambert JC, Schraen-Maschke S, Richard F et al. Association of plasma amyloid beta with risk of dementia: The prospective Three-City Study. Neurology 73(11), 847-853 (2009
59. Yaffe K, Weston A, Graff-Radford NR et al. Association of plasma beta-Amyloid level and cognitive reserve with subsequent cognitive decline. JAMA 305(3), 261-266 (2011
60. Watt AD, Perez KA, Rembach AR, Masters CL, Villemagne VL, Barnham KJ. Variability in blood-based amyloid-beta assays: The need for consensus on pre-Analytical processing. J. Alzheimers Dis. 30(2), 323-336 (2012
61. Fukumoto E, Sakai H, Fukumoto S, Yagi T, Takagi O, Kato Y. Cadherin-related neuronal receptors in incisor development. J. Dent. Res. 82(1), 17-22 (2003
62. Arvanitakis Z, Lucas JA, Younkin LH, Younkin SG, Graff-Radford NR. Serum creatinine levels correlate with plasma amyloid beta protein. Alzheimer Dis. Assoc. Disord. 16(3), 187-190 (2002
63. Kuller LH, Longstreth WT Jr, Arnold AM, Bernick C, Bryan RN, Beauchamp NJ Jr. White matter hyperintensity on cranial magnetic resonance imaging: A predictor of stroke. Stroke 35(8), 1821-1825 (2004
64. Lopez OL, Kuller LH, Mehta PD et al. Plasma amyloid levels and the risk of AD in normal subjects in the Cardiovascular Health Study. Neurology 70(19), 1664-1671 (2008
65. Blasko I, Kemmler G, Krampla W et al. Plasma amyloid beta protein 42 in non-demented persons aged 75 years: Effects of concomitant medication and medial temporal lobe atrophy. Neurobiol. Aging 26(8), 1135-1143 (2005
66. Toledo JB, Vanderstichele H, Figurski M et al. Factors affecting Aβplasma levels and their utility as biomarkers in ADNI. Acta Neuropathologica 122(4), 401-413 (2011
67. Rembach A, Faux NG, Watt AD et al. Changes in plasma amyloid beta in a longitudinal study of aging and Alzheimer's disease. Alzheimers Dement. doi:10.1016/j. jalz.2012.12.006 (2013) (Epub ahead of print
68. Villemagne VL, Perez KA, Pike KE et al. Blood borne Amyloid-beta dimer correlates with clinical markers of Alzheimer's disease. J. Neurosci. 30(18), 6315-6322 (2010
69. Watt AD, Perez KA, Faux NG et al. Increasing the predictive accuracy of amyloid-βblood-borne biomarkers in Alzheimer's disease. J. Alzheimers Dis. 24(1), 47-59 (2010
70. Pesini P, Perez-Grijalba V, Monleon I et al. Reliable measurements of the β-Amyloid pool in blood could help in the early diagnosis of AD. Int. J. Alzheimers Dis. 604141 (2012) (2012
71. Kiko T, Nakagawa K, Satoh A et al. Amyloid beta levels in human red blood cells. PLoS ONE 7(11), e49620 (2012
72. Mattson MP, Begley JG, Mark RJ, Furukawa K. Abeta25-35 induces rapid lysis of red blood cells: Contrast with Abeta1-42 and examination of underlying mechanisms. Brain Res. 771(1), 147-153 (1997
73. Mohanty JG, Eckley DM, Williamson JD, Launer LJ, Rifkind JM. Do red blood cell-beta-Amyloid interactions alter oxygen delivery in Alzheimer's disease? Adv. Exp. Med. Biol. 614, 29-35 (2008
74. Nakagawa K, Kiko T, Kuriwada S, Miyazawa T, Kimura F. Amyloid βinduces adhesion of erythrocytes to endothelial cells and affects endothelial viability and functionality. Biosci. Biotechnol. Biochem. 75(10), 2030-2033 (2011
75. Kosicek M, Hecimovic S. Phospholipids and Alzheimer's disease: Alterations, mechanisms and potential biomarkers. Int. J. Mol. Sci. 14(1), 1310-1322 (2013
76. Svennerholm L, Bostrom K, Helander CG, Jungbjer B. Membrane lipids in the aging human brain. J. Neurochem. 56(6), 2051-2059 (1991
77. Bjorkhem I. Crossing the barrier: Oxysterols as cholesterol transporters and metabolic modulators in the brain. J. Intern. Med. 260(6), 493-508 (2006
78. Pike LJ. The challenge of lipid rafts. J. Lipid Res. 50(Suppl.), S323-S328 (2009
79. Hicks DA, Nalivaeva NN, Turner AJ. Lipid rafts and Alzheimer's disease: Protein-lipid interactions and perturbation of signaling. Front. Physiol. 3, 189 (2012
80. Pernber Z, Blennow K, Bogdanovic N, Mansson JE, Blomqvist M. Altered distribution of the gangliosides GM1 and GM2 in Alzheimer's disease. Dement. Geriat. Cogn. Disord. 33(2-3), 174-188 (2012
81. Mahley RW. Apolipoprotein E: Cholesterol transport protein with expanding role in cell biology. Science 240(4852), 622-630 (1988
82. Hoe HS, Rebeck GW. Regulated proteolysis of APP and ApoE receptors. Mol. Neurobiol. 37(1), 64-72 (2008
83. Elliott DA, Tsoi K, Holinkova S et al. Isoform-specific proteolysis of apolipoprotein-E in the brain. Neurobiol. Aging 32(2), 257-271 (2011
84. Zhou W, Scott SA, Shelton SB, Crutcher KA. Cathepsin D-mediated proteolysis of apolipoprotein E: Possible role in Alzheimer's disease. Neuroscience 143(3), 689-701 (2006
85. Castano EM, Prelli F, Pras M, Frangione B. Apolipoprotein E carboxyl-Terminal fragments are complexed to amyloids A and L. Implications for amyloidogenesis and Alzheimer's disease. J. Biol. Chem. 270(29), 17610-17615 (1995
86. Tolar M, Marques MA, Harmony JA, Crutcher KA. Neurotoxicity of the 22 kDa thrombin-cleavage fragment of apolipoprotein E and related synthetic peptides is receptor-mediated. J. Neurosci. 17(15), 5678-5686 (1997
87. Panegyres PK, Goldblatt J, Walpole I, Connor C, Liebeck T, Harrop K. Genetic testing for Alzheimer's disease. Med. J. Aust. 172(7), 339-343 (2000
88. Akuffo EL, Davis JB, Fox SM et al. The discovery and early validation of novel plasma biomarkers in mild-To-moderate Alzheimer's disease patients responding to treatment with rosiglitazone. Biomarkers 13(6), 618-636 (2008
89. Taddei K, Clarnette R, Gandy SE, Martins RN. Increased plasma apolipoprotein E (apoE) levels in Alzheimer's disease. Neurosci. Lett. 223(1), 29-32 (1997
90. Lehtimaki T, Pirttila T, Mehta PD, Wisniewski HM, Frey H, Nikkari T. Apolipoprotein E (ApoE) polymorphism and its influence on ApoE concentrations in the cerebrospinal fluid in Finnish patients with Alzheimer's disease. Hum. Genet. 95(1), 39-42 (1995
91. Gupta VB, Laws SM, Villemagne VL et al. Plasma apolipoprotein E and Alzheimer disease risk: The AIBL study of aging. Neurology 76(12), 1091-1098 (2011
92. Siest G, Bertrand P, Herbeth B et al. Apolipoprotein E polymorphisms and concentration in chronic diseases and drug responses. Clin. Chem. Lab. Med. 38(9), 841-852 (2000
93. Fukumoto H, Ingelsson M, Garevik N et al. APOE epsilon 3/epsilon 4 heterozygotes have an elevated proportion of apolipoprotein E4 in cerebrospinal fluid relative to plasma, independent of Alzheimer's disease diagnosis. Exp. Neurol. 183(1), 249-253 (2003
94. Pfrieger FW. Cholesterol homeostasis and function in neurons of the central nervous system. Cell. Mol. Life Sci. 60(6), 1158-1171 (2003
95. Pitas RE, Boyles JK, Lee SH, Hui D, Weisgraber KH. Lipoproteins and their receptors in the central nervous system. Characterization of the lipoproteins in cerebrospinal fluid and identification of apolipoprotein B,E(LDL) receptors in the brain. J. Biol. Chem. 262(29), 14352-14360 (1987
96. Kivipelto M, Ngandu T, Fratiglioni L et al. Obesity and vascular risk factors at midlife and the risk of dementia and Alzheimer disease. Arch. Neurol. 62(10), 1556-1560 (2005
97. Notkola IL, Sulkava R, Pekkanen J et al. Serum total cholesterol, apolipoprotein E epsilon 4 allele, and Alzheimer's disease. Neuroepidemiology 17(1), 14-20 (1998
98. Whitmer RA, Sidney S, Selby J, Johnston SC, Yaffe K. Midlife cardiovascular risk factors and risk of dementia in late life. Neurology 64(2), 277-281 (2005
99. Stewart R, White LR, Xue QL, Launer LJ. Twenty-six-year change in total cholesterol levels and incident dementia: The Honolulu-Asia Aging Study. Arch. Neurol. 64(1), 103-107 (2007
100. Beydoun MA, Beason-Held LL, Kitner-Triolo MH et al. Statins and serum cholesterol's associations with incident dementia and mild cognitive impairment. J. Epidemiol. Community Health 65(11), 949-957 (2011
101. Li G, Shofer JB, Kukull WA et al. Serum cholesterol and risk of Alzheimer disease: A community-based cohort study. Neurology 65(7), 1045-1050 (2005
102. Mainous AG 3rd, Eschenbach SL, Wells BJ, Everett CJ, Gill JM. Cholesterol, transferrin saturation, and the development of dementia and Alzheimer's disease: Results from an 18-year population-based cohort. Fam. Med. 37(1), 36-42 (2005
103. Romas SN, Tang MX, Berglund L, Mayeux R. APOE genotype, plasma lipids, lipoproteins, and AD in community elderly. Neurology 53(3), 517-521 (1999
104. Tan ZS, Seshadri S, Beiser A et al. Plasma total cholesterol level as a risk factor for Alzheimer disease: The Framingham Study. Arch. Intern. Med. 163(9), 1053-1057 (2003
105. Sato Y, Suzuki I, Nakamura T, Bernier F, Aoshima K, Oda Y. Identification of a new plasma biomarker of Alzheimer's disease using metabolomics technology. J. Lipid Res. 53(3), 567-576 (2012
106. Wong WB, Lin VW, Boudreau D, Devine EB. Statins in the prevention of dementia and Alzheimer's disease: A meta-Analysis of observational studies and an assessment of confounding. Pharmacoepidemiol. Drug Saf. 22(4), 345-358 (2013
107. Leoni V. Oxysterols as markers of neurological disease-A review. Scand. J. Clin. Lab. Invest. 69(1), 22-25 (2009
108. Hughes TM, Rosano C, Evans RW, Kuller LH. Brain cholesterol metabolism, oxysterols, and dementia. J. Alzheimers Dis. 33(4), 891-911 (2013
109. Han X, M Holtzman D, McKeel DW Jr, Kelley J, Morris JC. Substantial sulfatide deficiency and ceramide elevation in very early Alzheimer's disease: Potential role in disease pathogenesis. J. Neurochem. 82(4), 809-818 (2002
110. Cutler RG, Kelly J, Storie K et al. Involvement of oxidative stress-induced abnormalities in ceramide and cholesterol metabolism in brain aging and Alzheimer's disease. Proc. Natl Acad. Sci. USA 101(7), 2070-2075 (2004
111. He X, Huang Y, Li B, Gong CX, Schuchman EH. Deregulation of sphingolipid metabolism in Alzheimer's disease. Neurobiol. Aging 31(3), 398-408 (2010
112. Han X, Rozen S, Boyle SH et al. Metabolomics in early Alzheimer's disease: Identification of altered plasma sphingolipidome using shotgun lipidomics. PLoS ONE 6(7), e21643 (2011
113. Mielke MM, Haughey NJ, Ratnam Bandaru VV et al. Plasma ceramides are altered in mild cognitive impairment and predict cognitive decline and hippocampal volume loss. Alzheimers Dement. 6(5), 378-385 (2010
114. Mielke MM, Bandaru VV, Haughey NJ et al Serum ceramides increase the risk of Alzheimer disease: The Women's Health and Aging Study II. Neurology 79(7), 633-641 (2012
115. Li NJ, Liu WT, Li W et al. Plasma metabolic profiling of Alzheimer's disease by liquid chromatography/mass spectrometry. Clin. Biochem. 43(12), 992-997 (2010
116. Wallin A, Gottfries CG, Karlsson I, Svennerholm L. Decreased myelin lipids in Alzheimer's disease and vascular dementia. Acta Neurol. Scand. 80(4), 319-323 (1989
117. Dross K, Kewitz H. Concentration and origin of choline in the rat brain. Naunyn Schmiedebergs Arch. Pharmacol. 274(1), 91-106 (1972
118. Igarashi M, Ma K, Gao F, Kim HW, Rapoport SI, Rao JS. Disturbed choline plasmalogen and phospholipid fatty acid concentrations in Alzheimer's disease prefrontal cortex. J. Alzheimers Dis. 24(3), 507-517 (2011
119. Walter A, Korth U, Hilgert M et al. Glycerophosphocholine is elevated in cerebrospinal fluid of Alzheimer patients. Neurobiol. Aging 25(10), 1299-1303 (2004
120. Nitsch RM, Blusztajn JK, Pittas AG, Slack BE, Growdon JH, Wurtman RJ. Evidence for a membrane defect in Alzheimer disease brain. Proc. Natl Acad. Sci. USA 89(5), 1671-1675 (1992
121. Ellison DW, Beal MF, Martin JB. Phosphoethanolamine and ethanolamine are decreased in Alzheimer's disease and Huntington's disease. Brain Res. 417(2), 389-392 (1987
122. Molina JA, Jimenez-Jimenez FJ, Vargas C et al. Cerebrospinal fluid levels of non-neurotransmitter amino acids in patients with Alzheimer's disease. J. Neural Transm. 105(2-3), 279-286 (1998
123. Ginsberg L, Rafique S, Xuereb JH, Rapoport SI, Gershfeld NL. Disease and anatomic specificity of ethanolamine plasmalogen deficiency in Alzheimer's disease brain. Brain Res. 698(1-2), 223-226 (1995
124. Han X, Holtzman DM, McKeel DW Jr. Plasmalogen deficiency in early Alzheimer's disease subjects and in animal models: Molecular characterization using electrospray ionization mass spectrometry. J. Neurochem. 77(4), 1168-1180 (2001
125. Han X. Lipid alterations in the earliest clinically recognizable stage of Alzheimer's disease: Implication of the role of lipids in the pathogenesis of Alzheimer's disease. Curr. Alzheimer Res. 2(1), 65-77 (2005
126. Goodenowe DB, Cook LL, Liu J et al. Peripheral ethanolamine plasmalogen deficiency: A logical causative factor in Alzheimer's disease and dementia. J. Lipid Res. 48(11), 2485-2498 (2007
127. Wood PL, Mankidy R, Ritchie S et al. Circulating plasmalogen levels and Alzheimer Disease Assessment Scale-Cognitive scores in Alzheimer patients. J. Phychiatry Neurosci. 35(1), 59-62 (2010
128. Pratico D. The neurobiology of isoprostanes and Alzheimer's disease. Biochim. Biophys. Acta 1801(8), 930-933 (2010
129. Lovell MA, Markesbery WR. Oxidative damage in mild cognitive impairment and early Alzheimer's disease. J. Neurosci. Res. 85(14), 3036-3040 (2007
130. Montine TJ, Quinn J, Kaye J, Morrow JD. F(2)-isoprostanes as biomarkers of late-onset Alzheimer's disease. J. Mol. Neurosci. 33(1), 114-119 (2007
131. Pratico D, Clark CM, Lee VM, Trojanowski JQ, Rokach J, Fitzgerald GA. Increased 8,12-iso-iPF2alpha-VI in Alzheimer's disease: Correlation of a noninvasive index of lipid peroxidation with disease severity. Ann. Neurol. 48(5), 809-812 (2000
132. Pratico D, Clark CM, Liun F, Rokach J, Lee VY, Trojanowski JQ. Increase of brain oxidative stress in mild cognitive impairment: A possible predictor of Alzheimer disease. Arch. Neurol. 59(6), 972-976 (2002
133. Irizarry MC, Yao Y, Hyman BT, Growdon JH, Pratico D. Plasma F2A isoprostane levels in Alzheimer's and Parkinson's disease. Neurodegene. Dis. 4(6), 403-405 (2007
134. Cooper-Knock J, Kirby J, Ferraiuolo L, Heath PR, Rattray M, Shaw PJ. Gene expression profiling in human neurodegenerative disease. Nat. Rev. Neurol. 8(9), 518-530 (2012
135. Booij BB, Lindahl T, Wetterberg P et al. A gene expression pattern in blood for the early detection of Alzheimer's disease. J. Alzheimers Dis. 23(1), 109-119 (2011
136. Rye PD, Booij BB, Grave G et al. A novel blood test for the early detection of Alzheimer's disease. J. Alzheimers Dis. 23(1), 121-129 (2011
137. Fehlbaum-Beurdeley P, Jarrige-Le Prado AC, Pallares D et al. Toward an Alzheimer's disease diagnosis via high-resolution blood gene expression. Alzheimers Dement. 6(1), 25-38 (2010
138. Lunnon K, Sattlecker M, Furney SJ et al. A blood gene expression marker of early Alzheimer's disease. J. Alzheimers Dis. 33(3), 737-753 (2013
139. Bellingham SA, Guo BB, Coleman BM, Hill AF. Exosomes: Vehicles for the transfer of toxic proteins associated with neurodegenerative diseases? Front. Physiol. 3, 124 (2012
140. Sharples RA, Vella LJ, Nisbet RM et al. Inhibition of gamma-secretase causes increased secretion of amyloid precursor protein C-Terminal fragments in association with exosomes. FASEB J. 22(5), 1469-1478 (2008
141. Geekiyanage H, Jicha GA, Nelson PT, Chan C. Blood serum miRNA: Non-invasive biomarkers for Alzheimer's disease. Exp. Neurol. 235(2), 491-496 (2012
142. Sheinerman KS, Tsivinsky VG, Crawford F, Mullan MJ, Abdullah L, Umansky SR. Plasma microRNA biomarkers for detection of mild cognitive impairment. Aging 4(9), 590-605 (2012
143. Adlard PA, Bush AI. Metals and Alzheimer's disease. J. Alzheimers Dis. 10(2-3), 145-163 (2006
144. Collingwood JF, Mikhaylova A, Davidson M et al. In situ characterization and mapping of iron compounds in Alzheimer's disease tissue. J. Alzheimers Dis. 7(4), 267-272 (2005
145. Deibel MA, Ehmann WD, Markesbery WR. Copper, iron, and zinc imbalances in severely degenerated brain regions in Alzheimer's disease: Possible relation to oxidative stress. J. Neurol. Sci. 143(1-2), 137-142 (1996
146. Lovell MA, Robertson JD, Teesdale WJ, Campbell JL, Markesbery WR. Copper, iron and zinc in Alzheimer's disease senile plaques. J. Neurol. Sci. 158(1), 47-52 (1998
147. Miller LM, Wang Q, Telivala TP, Smith RJ, Lanzirotti A, Miklossy J. Synchrotron-based infrared and X-ray imaging shows focalized accumulation of Cu and Zn co-localized with beta-Amyloid deposits in Alzheimer's disease. J. Struct. Biol. 155(1), 30-37 (2006
148. Bush AI, Tanzi RE. Therapeutics for Alzheimer's disease based on the metal hypothesis. Neurotherapeutics 5(3), 421-432 (2008
149. Altamura S, Muckenthaler MU. Iron toxicity in diseases of aging: Alzheimer's disease, Parkinson's disease and atherosclerosis. J. Alzheimers Dis. 16(4), 879-895 (2009
150. Maynard CJ, Cappai R, Volitakis I et al. Overexpression of Alzheimer's disease amyloid-beta opposes the age-dependent elevations of brain copper and iron. J. Biol. Chem. 277(47), 44670-44676 (2002
151. Bellingham SA, Ciccotosto GD, Needham BE et al. Gene knockout of amyloid precursor protein and amyloid precursor-like protein-2 increases cellular copper levels in primary mouse cortical neurons and embryonic fibroblasts. J. Neurochem. 91(2), 423-428 (2004
152. White AR, Reyes R, Mercer JF et al. Copper levels are increased in the cerebral cortex and liver of APP and APLP2 knockout mice. Brain Res. 842(2), 439-444 (1999
153. Bressler JP, Olivi L, Cheong JH, Kim Y, Maerten A, Bannon D. Metal transporters in intestine and brain: Their involvement in metal-Associated neurotoxicities. Hum. Exp. Toxicol. 26(3), 221-229 (2007
154. Gerhardsson L, Lundh T, Minthon L, Londos E. Metal concentrations in plasma and cerebrospinal fluid in patients with Alzheimer's disease. Dement. Geriat. Cogn. Disord. 25(6), 508-515 (2008
155. Gonzalez C, Martin T, Cacho J et al. Serum zinc, copper, insulin and lipids in Alzheimer's disease epsilon 4 apolipoprotein E allele carriers. Eur. J. Clin. Invest. 29(7), 637-642 (1999
156. Roberts NB, Clough A, Bellia JP, Kim JY. Increased absorption of aluminium from a normal dietary intake in dementia. J. Inorg. Biochem. 69(3), 171-176 (1998
157. Smorgon C, Mari E, Atti AR et al. Trace elements and cognitive impairment: An elderly cohort study. Arch. Gerontol. Geriatr. Suppl. (9), 393-402 (2004
158. Squitti R, Barbati G, Rossi L et al. Excess of nonceruloplasmin serum copper in AD correlates with MMSE, CSF [beta]-Amyloid, and h-Tau. Neurology 67(1), 76-82 (2006
159. Squitti R, Bressi F, Pasqualetti P et al. Longitudinal prognostic value of serum 'free' copper in patients with Alzheimer disease. Neurology 72(1), 50-55 (2009
160. Taylor GA, Ferrier IN, McLoughlin IJ et al. Gastrointestinal absorption of aluminium in Alzheimer's disease: Response to aluminium citrate. Age Ageing 21(2), 81-90 (1992
161. Vural H, Demirin H, Kara Y, Eren I, Delibas N. Alterations of plasma magnesium, copper, zinc, iron and selenium concentrations and some related erythrocyte antioxidant enzyme activities in patients with Alzheimer's disease. J. Trace Elem. Med. Biol. 24(3), 169-173 (2010
162. Zapatero MD, Garcia de Jalon A, Pascual F, Calvo ML, Escanero J, Marro A. Serum aluminum levels in Alzheimer's disease and other senile dementias. Biol. Trace Elem. Res. 47(1-3), 235-240 (1995
163. Rossi L, Squitti R, Calabrese L, Rotilio G, Rossini PM. Alteration of peripheral markers of copper homeostasis in Alzheimer's disease patients: Implications in aetiology and therapy. J. Nutr. Health Aging 11(5), 408-417 (2007
164. Squitti R, Lupoi D, Pasqualetti P et al. Elevation of serum copper levels in Alzheimer's disease. Neurology 59(8), 1153-1161 (2002
165. Bucossi S, Ventriglia M, Panetta V et al. Copper in Alzheimer's disease: A meta-Analysis of serum, plasma, and cerebrospinal fluid studies. J. Alzheimers Dis. 24(1), 175-185 (2011
166. Brewer GJ, Kanzer SH, Zimmerman EA, Celmins DF, Heckman SM, Dick R. Copper and ceruloplasmin abnormalities in Alzheimer's disease. Am. J. Alzheimers Dis. Other Demen. 25(6), 490-497 (2010
167. Molina JA, Jimenez-Jimenez FJ, Aguilar MV et al. Cerebrospinal fluid levels of transition metals in patients with Alzheimer's disease. J. Neural Transm. 105(4-5), 479-488 (1998
168. Ozcankaya R, Delibas N. Malondialdehyde, superoxide dismutase, melatonin, iron, copper, and zinc blood concentrations in patients with Alzheimer disease: Cross-sectional study. Croat. Med. J. 43(1), 28-32 (2002
169. Sedighi BSM. A, Shariati M. A study of serum copper and ceruloplasmin in Alzheimer's disease in Kerman, Iran. Neurology Asia 11, 107-109 (2006
170. Bocca B, Forte G, Petrucci F et al. Monitoring of chemical elements and oxidative damage in patients affected by Alzheimer's disease. Ann. Ist. Super. Sanita 41(2), 197-203 (2005
171. Squitti R, Pasqualetti P, Cassetta E et al. Elevation of serum copper levels discriminates Alzheimer's disease from vascular dementia. Neurology 60(12), 2013-2014 (2003
172. Squitti R, Pasqualetti P, Dal Forno G et al. Excess of serum copper not related to ceruloplasmin in Alzheimer disease. Neurology 64(6), 1040-1046 (2005
173. Squitti R, Ventriglia M, Barbati G et al. 'Free' copper in serum of Alzheimer's disease patients correlates with markers of liver function. J. Neural Transm. 114(12), 1589-1594 (2007
174. Zappasodi F, Salustri C, Babiloni C et al. An observational study on the influence of the APOE-epsilon4 allele on the correlation between 'free' copper toxicosis and EEG activity in Alzheimer disease. Brain Res. 1215, 183-189 (2008
175. Arnal N, Cristalli DO, De Alaniz MJ, Marra CA. Clinical utility of copper, ceruloplasmin, and metallothionein plasma determinations in human neurodegenerative patients and their first-degree relatives. Brain Res. 1319, 118-130 (2010
176. Rembach A, Doecke JD, Roberts BR et al. Longitudinal analysis of serum copper and ceruloplasmin in Alzheimer's disease. J. Alzheimers Dis. 34(1), 171-182 (2013
177. Maurer I, Zierz S, Moller HJ. A selective defect of cytochrome c oxidase is present in brain of Alzheimer disease patients. Neurobiol. Aging 21(3), 455-462 (2000
178. Cottrell DA, Blakely EL, Johnson MA, Ince PG, Turnbull DMMitochondrial enzyme-deficient hippocampal neurons and choroidal cells in AD. Neurology 57(2), 260-264 (2001
179. De Deyn PP, Hiramatsu M, Borggreve F et al. Superoxide dismutase activity in cerebrospinal fluid of patients with dementia and some other neurological disorders. Alzheimer Dis. Assoc. Disord. 12(1), 26-32 (1998
180. Omar RA, Chyan YJ, Andorn AC, Poeggeler B, Robakis NK, Pappolla MA. Increased expression but reduced activity of antioxidant enzymes in Alzheimer's
181. Milne DB, Johnson PE. Assessment of copper status: Effect of age and gender on reference ranges in healthy adults. Clin. Chem. 39(5), 883-887 (1993
182. Lewis AJ. The role of copper in inflammatory disorders. Agents Actions 15(5-6), 513-519 (1984
183. Squitti R, Quattrocchi CC, Salustri C, Rossini PM. Ceruloplasmin fragmentation is implicated in 'free' copper deregulation of Alzheimer's disease. Prion 2(1), 23-27 (2008
184. Baum L, Chan IH, Cheung SK et al. Serum zinc is decreased in Alzheimer's disease and serum arsenic correlates positively with cognitive ability. Biometals 23(1), 173-179 (2010
185. Basun H, Forssell LG, Wetterberg L, Winblad B. Metals and trace elements in plasma and cerebrospinal fluid in normal aging and Alzheimer's disease. J. Neural Transm. Park. Dis. Dement. Sect. 3(4), 231-258 (1991
186. Brewer GJ, Kanzer SH, Zimmerman EA et al. Subclinical zinc deficiency in Alzheimer's disease and Parkinson's disease. Am. J. Alzheimers Dis. Other Dement. 25(7), 572-575 (2010
187. Cornett CR, Markesbery WR, Ehmann WD. Imbalances of trace elements related to oxidative damage in Alzheimer's disease brain. Neurotoxicology 19(3), 339-345 (1998
188. Religa D, Strozyk D, Cherny RA et al. Elevated cortical zinc in Alzheimer disease. Neurology 67(1), 69-75 (2006
189. Ahluwalia N, Gordon MA, Handte G et al. Iron status and stores decline with age in Lewis rats. J. Nutr. 130(9), 2378-2383 (2000
190. Strozyk D, Launer LJ, Adlard PA et al. Zinc and copper modulate Alzheimer Abeta levels in human cerebrospinal fluid. Neurobiol. Aging 30(7), 1069-1077 (2009
191. Mueller C, Schrag M, Crofton A et al. Altered serum iron and copper homeostasis predicts cognitive decline in mild cognitive impairment. J. Alzheimers Dis. 29(2), 341-350 (2012
192. Ferretti MT, Cuello AC. Does a pro-inflammatory process precede Alzheimer's disease and mild cognitive impairment? Curr. Alzheimer Res. 8(2), 164-174 (2011
193. Strang F, Scheichl A, Chen YC et al. Amyloid plaques dissociate pentameric to monomeric C-reactive protein: A novel pathomechanism driving cortical inflammation in Alzheimer's disease? Brain Pathol. 22(3), 337-346 (2012
194. McGeer EG, McGeer PL. Inflammatory processes in Alzheimer's disease. Prog. Neuropsychopharmacol. Biol. Psychiatry 27(5), 741-749 (2003
195. Wyss-Coray T, Mucke L. Inflammation in neurodegenerative disease-A double-edged sword. Neuron 35(3), 419-432 (2002
196. Meyer-Luehmann M, Spires-Jones TL, Prada C et al. Rapid appearance and local toxicity of amyloid-beta plaques in a mouse model of Alzheimer's disease. Nature 451(7179), 720-724 (2008
197. Holmes C, Butchart J. Systemic inflammation and Alzheimer's disease. Biochem. Soc. Trans. 39(4), 898-901 (2011
198. Schwab C, Mcgeer PL. Inflammatory aspects of Alzheimer disease and other neurodegenerative disorders. J. Alzheimers Dis. 13(4), 359-369 (2008
199. Walsh SR, Cook EJ, Goulder F, Justin TA, Keeling NJ. Neutrophil- lymphocyte ratio as a prognostic factor in colorectal cancer. J. Surg. Oncol. 91(3), 181-184 (2005
200. Sarraf KM, Belcher E, Raevsky E, Nicholson AG, Goldstraw P, Lim E. Neutrophil/ lymphocyte ratio and its association with survival after complete resection in non-small cell lung cancer. J. Thorac. Cardiovasc. Surg. 137(2), 425-428 (2009
201. Kuyumcu ME, Yesil Y, Ozturk ZA et al. The evaluation of neutrophil-lymphocyte ratio in Alzheimer's disease. Dement. Geriat. Cogn. Disord. 34(2), 69-74 (2012
202. Imtiaz F, Shafique K, Mirza SS, Ayoob Z, Vart P, Rao S. Neutrophil lymphocyte ratio as a measure of systemic inflammation in prevalent chronic diseases in Asian population. Int. Arch. Med. 5(1), 2 (2012
203. Leuner K, Schulz K, Schutt T et al. Peripheral mitochondrial dysfunction in Alzheimer's disease: Focus on lymphocytes. Mol. Neurobiol. 46(1), 194-204 (2012
204. Swardfager W, Lanctot K, Rothenburg L, Wong A, Cappell J, Herrmann N. A meta-Analysis of cytokines in Alzheimer's disease. Biol. Psychiatry 68(10), 930-941 (2010
205. Lee KS, Chung JH, Choi TK, Suh SY, Oh BH, Hong CH. Peripheral cytokines and chemokines in Alzheimer's disease. Dement. Geriat. Cogn. Disord. 28(4), 281-287 (2009
206. Potempa J, Korzus E, Travis J. The serpin superfamily of proteinase inhibitors: Structure, function, and regulation. J. Biol. Chem. 269(23), 15957-15960 (1994
207. Gollin PA, Kalaria RN, Eikelenboom P, Rozemuller A, Perry G. Alpha 1-Antitrypsin and alpha 1-Antichymotrypsin are in the lesions of Alzheimer's disease. Neuroreport 3(2), 201-203 (1992
208. Liao PC, Yu L, Kuo CC, Lin C, Kuo YM. Proteomics analysis of plasma for potential biomarkers in the diagnosis of Alzheimer's disease. Proteomics Clin. Appl. 1(5), 506-512 (2007
209. Sihlbom C, Davidsson P, Sjogren M, Wahlund LO, Nilsson CL. Structural and quantitative comparison of cerebrospinal fluid glycoproteins in Alzheimer's disease patients and healthy individuals. Neurochem. Res. 33(7), 1332-1340 (2008
210. Nielsen HM, Minthon L, Londos E et al. Plasma and CSF serpins in Alzheimer disease and dementia with Lewy bodies. Neurology 69(16), 1569-1579 (2007
211. Choi J, Malakowsky CA, Talent JM, Conrad CC, Gracy RW. Identification of oxidized plasma proteins in Alzheimer's disease. Biochem. Biophys. Res. Commun. 293(5), 1566-1570 (2002
212. Yu HL, Chertkow HM, Bergman H, Schipper HM. Aberrant profiles of native and oxidized glycoproteins in Alzheimer plasma. Proteomics 3(11), 2240-2248 (2003
213. Sun YX, Minthon L, Wallmark A, Warkentin S, Blennow K, Janciauskiene S. Inflammatory markers in matched plasma and cerebrospinal fluid from patients with Alzheimer's disease. Dement. Geriat. Cogn. Disord. 16(3), 136-144 (2003
214. Nuutinen T, Suuronen T, Kauppinen A, Salminen A. Clusterin: A forgotten player in Alzheimer's disease. Brain Res. Rev. 61(2), 89-104 (2009
215. Kim N, Han JY, Roh GS et al. Nuclear clusterin is associated with neuronal apoptosis in the developing rat brain upon ethanol exposure. Alcohol. Clin. Exp. Res. 36(1), 72-82 (2012
216. Lambert JC, Heath S, Even G et al. Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease. Nat. Genet. 41(10), 1094-1099 (2009
217. Seshadri S, Fitzpatrick AL, Ikram MA et al. Genome-wide analysis of genetic loci associated with Alzheimer disease. JAMA 303(18), 1832-1840 (2010
218. Harold D, Abraham R, Hollingworth P et al. Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. Nat. Genet. 41(10), 1088-1093 (2009
219. Schrijvers EM, Koudstaal PJ, Hofman A, Breteler MM. Plasma clusterin and the risk of Alzheimer disease. JAMA 305(13), 1322-1326 (2011
220. Thambisetty M, Simmons A, Velayudhan L et al. Association of plasma clusterin concentration with severity, pathology, and progression in Alzheimer disease. Arch. Gen. Psychiatry 67(7), 739-748 (2010
221. Silajdzic E, Minthon L, Bjorkqvist M, Hansson O. No diagnostic value of plasma clusterin in Alzheimer's disease. PLoS ONE 7(11), e50237 (2012
222. Hu Y, Hosseini A, Kauwe JS et al. Identification and validation of novel CSF biomarkers for early stages of Alzheimer's disease. Proteomics Clin. Appl. 1(11), 1373-1384 (2007
223. Kalaria RN, Golde T, Kroon SN, Perry G. Serine protease inhibitor antithrombin III and its messenger RNA in the pathogenesis of Alzheimer's disease. Am. J. Pathol. 143(3), 886-893 (1993
224. Akiyama H, Ikeda K, Kondo H, McGeer PL. Thrombin accumulation in brains of patients with Alzheimer's disease. Neurosci. Lett. 146(2), 152-154 (1992
225. Ho GJ, Smirnova IV, Akaaboune M, Hantai D, Festoff BW. Serine proteases and their serpin inhibitors in Alzheimer's disease. Biomed Pharmacother. 48(7), 296-304 (1994
226. Pike CJ, Vaughan PJ, Cunningham DD, Cotman CW. Thrombin attenuates neuronal cell death and modulates astrocyte reactivity induced by beta-Amyloid in vitro. J. Neurochem. 66(4), 1374-1382 (1996
227. Mhatre M, Nguyen A, Kashani S, Pham T, Adesina A, Grammas P. Thrombin, a mediator of neurotoxicity and memory impairment. Neurobiol. Aging 25(6), 783-793 (2004
228. Okazaki T, Yanagisawa Y, Nagai T. Analysis of the affinity of each haptoglobin polymer for hemoglobin by two-dimensional affinity electrophoresis. Clin. Chim. Acta 258(2), 137-144 (1997
229. Sadrzadeh SM, Graf E, Panter SS, Hallaway PE, Eaton JW. Hemoglobin. A biologic fenton reagent. J. Biol. Chem. 259(23), 14354-14356 (1984
230. Gutteridge JM. The antioxidant activity of haptoglobin towards haemoglobin-stimulated lipid peroxidation. Biochim. Biophys. Acta 917(2), 219-223 (1987
231. Abraham JD, Calvayrac-Pawlowski S, Cobo S et al. Combined measurement of PEDF, haptoglobin and tau in cerebrospinal fluid improves the diagnostic discrimination between alzheimer's disease and other dementias. Biomarkers 16(2), 161-171 (2011
232. Zhang R, Barker L, Pinchev D et al. Mining biomarkers in human sera using proteomic tools. Proteomics 4(1), 244-256 (2004
233. Johnson G, Brane D, Block W et al. Cerebrospinal fluid protein variations in common to Alzheimer's disease and schizophrenia. Appl. Theor. Electrophor. 3(2), 47-53 (1992
234. Mattila KM, Pirttila T, Blennow K, Wallin A, Viitanen M, Frey H. Altered blood-brain-barrier function in Alzheimer's disease? Acta Neurol. Scand. 89(3), 192-198 (1994
235. Brown RC, Han Z, Cascio C, Papadopoulos V. Oxidative stress-mediated DHEA formation in Alzheimer's disease pathology. Neurobiol. Aging 24(1), 57-65 (2003
236. Rammouz G, Lecanu L, Aisen P, Papadopoulos V. A lead study on oxidative stress-mediated dehydroepiandrosterone formation in serum: The biochemical basis for a diagnosis of Alzheimer's disease. J. Alzheimers Dis. 24(Suppl. 2), 5-16 (2011
237. Taurines R, Dudley E, Grassl J et al. Proteomic research in psychiatry. J. Psychopharmacol. 25(2), 151-196 (2011
238. Lista S, Faltraco F, Prvulovic D, Hampel H. Blood and plasma-based proteomic biomarker research in Alzheimer's disease. Prog. Neurobiol. 101-102, 1-17 (2013
239. Cutler P, Akuffo EL, Bodnar WM et al. Proteomic identification and early validation of complement 1 inhibitor and pigment epithelium-derived factor: Two novel biomarkers of Alzheimer's disease in human plasma. Proteomics Clin. Appl. 2(4), 467-477 (2008
240. Johnstone D, Milward EA, Berretta R, Moscato P. Multivariate protein signatures of pre-clinical Alzheimer's disease in the Alzheimer's disease neuroimaging initiative (ADNI) plasma proteome dataset. PLoS ONE 7(4), e34341 (2012
241. Song F, Poljak A, Smythe GA, Sachdev P. Plasma biomarkers for mild cognitive impairment and Alzheimer's disease. Brain Res. Rev. 61(2), 69-80 (2009
242. Kawarabayashi T, Shoji M. Plasma biomarkers of Alzheimer's disease. Curr. Opin. Psychiatry 21(3), 260-267 (2008
243. Ray S, Britschgi M, Herbert C et al. Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins. Nat. Med. 13(11), 1359-1362 (2007
244. Soares HD, Chen Y, Sabbagh M, Roher A, Schrijvers E, Breteler M. Identifying early markers of Alzheimer's disease using quantitative multiplex proteomic immunoassay panels. Ann. NY Acad. Sci. 1180, 56-67 (2009
245. Marksteiner J, Kemmler G, Weiss EM et al. Five out of 16 plasma signaling proteins are enhanced in plasma of patients with mild cognitive impairment and Alzheimer's disease. Neurobiol. Aging 32(3), 539-540 (2011
246. Rocha de Paula M, Gómez Ravetti M, Berretta R, Moscato P. Differences in abundances of cell-signalling proteins in blood reveal novel biomarkers for early detection of clinical Alzheimer's disease. PLoS ONE 6(3), e17481 (2011
247. O'Bryant SE, Xiao G, Barber R et al. A blood-based screening tool for Alzheimer's disease that spans serum and plasma: Findings from TARC and ADNI. PLoS ONE 6(12), e28092 (2011
248. Doecke JD, Laws SM, Faux NG et al. Blood-based protein biomarkers for diagnosis of Alzheimer disease. Arch. Neurol. 69(10), 1318-1325 (2012
249. Soares HD, Potter WZ, Pickering E et al. Plasma biomarkers associated with the apolipoprotein E genotype and Alzheimer disease. Arch. Neurol. 69(10), 1310-1317 (2012
250. Bazenet C, Lovestone S. Plasma biomarkers for Alzheimer's disease: Much needed but tough to find. Biomarkers Med. 6(4), 441-454 (2012
251. Kraemer S, Vaught JD, Bock C et al. From SOMAmer-based biomarker discovery to diagnostic and clinical applications: A SOMAmer-based, streamlined multiplex proteomic assay. PLoS ONE 6(10), e26332 (2011
252. Galimberti D, Ghezzi L, Scarpini E. Immunotherapy against amyloid pathology in Alzheimer's disease. J. Neurol. Sci. doi:10.1016/j.jns.2012.12.013 (2013) (Epub ahead of print
253. Manzone TA, Dam HQ, Soltis D, Sagar VV. Blood volume analysis: A new technique and new clinical interest reinvigorate a classic study. J. Nucl. Med. Technol. 35(2), 55-63; quiz 77, 79 (2007